|
Major Depressive Disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Moreover, logistic regression analyses correctly classified BD and MDD patients with 98.1% accuracy, using a combination of IL-6, IL-8, ST2, sTNFR2 (directly associated with BD) and IL-12 and TNF-α (directly associated with MDD).
|
31693974 |
2020 |
|
Major Depressive Disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study suggests that in patients who have experienced AIS, there is no significant relationship between major depression and basal proinflammatory cytokines (TNF-α, IL-1 β, IL-18), BDNF, and NSE.
|
31142907 |
2020 |
|
Major Depressive Disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
A specific stress-induced increase in glucose and TNF-α was revealed in the MDD group, which was absent in control subjects.
|
30564974 |
2019 |
|
Major Depressive Disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Several studies have reported that increased TNF-α might be associated with tryptophan depletion, which eventually could result in MDD.
|
31561419 |
2019 |
|
Major Depressive Disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
The up-regulation of pro-inflammatory agents, amongst them tumor necrosis factor (TNF), may represent low-grade inflammation in major depression.
|
31622870 |
2019 |
|
Major Depressive Disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of the study was to explore TNF-α, IL-1β, CXCL12, CCL2, CCL11 (eotaxin-1) and CX3CL1 (fractalkine) as potential biomarkers to identify comorbid MDD and to distinguish primary MDD from substance-induced MDD in patients with substance disorders.
|
30870525 |
2019 |
|
Major Depressive Disorder
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Accumulating evidence has confirmed the association between chronic inflammation and MDD, which is manifested by increased levels of the C-reactive protein, as well as pro-inflammatory cytokines, such as Interleukin 1 beta, Interleukin 6, and the Tumor necrosis factor alpha.
|
31075818 |
2019 |
|
Major Depressive Disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Studies were included if they used SSRI monotherapy and peripheral levels of interleukin (IL)-1β, IL-2, IL-4, IL-6, IL-10, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ were measured before and after treatment in patients with MDD.
|
30797959 |
2019 |
|
Major Depressive Disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
41 SNPs in 8 inflammatory genes: interleukin (IL) 1-β, IL2, IL6, IL6R, IL10, IL18, tumor necrosis factor (TNF)-α and interferon (IFN)-γ were genotyped in 153 patients with MDD, who were evaluated with the Mausdley Staging Method to determine treatment response profiles.
|
31100612 |
2019 |
|
Major Depressive Disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using dichotomized cytokine levels, CXCL1/GRO and TNF-α were negatively associated with MDD.
|
30826620 |
2019 |
|
Major Depressive Disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
The GSEA suggested that tumor necrosis factor signaling pathway, Toll-like receptor signaling pathway, apoptosis pathway, and NF-kappa B signaling pathway are all crucial in the development of MDD.
|
31275757 |
2019 |
|
Major Depressive Disorder
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
However, an interactional effect of trauma with stressor type was found in the remitted MDD group: trauma was associated with higher cortisol levels only after adding immunological to psychosocial stress, and with lower TNF-α levels in response to vaccination.
|
31847190 |
2019 |
|
Major Depressive Disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor-α (TNF-α), a pro-inflammatory cytokine considered to be implicated in the pathogenesis of major depressive disorder, is a critical regulator of neuronal cell fate.
|
30840161 |
2019 |
|
Major Depressive Disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Moreover, a significant interaction effect of 'TNF-α × treatment' was found in MPFC-striatum FC in MDD patients (p = 0.002), and the significance remained after adjusted for age, gender, head motion, and episode of disease.
|
30520409 |
2019 |
|
Major Depressive Disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of the present study was to evaluate the plasma nesfatin-1, corticosterone, and inflammatory cytokine (IL-6, CRP, and TNF-α) concentrations cross-sectionally in patients with major depressive disorder.
|
29427582 |
2018 |
|
Major Depressive Disorder
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
After 12 weeks, TNF-α, IL-4, and IL-13 levels became lower in MDD patients than in the other two groups regardless of the patients' response to treatment while the levels of TNF-α and IL-4 increased only in the BDD responders.
|
29778935 |
2018 |
|
Major Depressive Disorder
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TNF-α expression was examined in the dorsolateral prefrontal cortex of the postmortem brains of persons with and without major depressive disorder who died by suicide and of persons with major depressive disorder who died of causes other than suicide.
|
29361849 |
2018 |
|
Major Depressive Disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to test whether rs1799724, an SNP of TNF-α, contributes to the neuroanatomical changes in MDD.
|
30310056 |
2018 |
|
Major Depressive Disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
To compare I&O biomarkers between MDD and BD we assessed serum levels of thiobarbituric acid reactive substances (TBARS; a lipid peroxidation marker), soluble interleukin-2 receptor (sIL-2R), sIL-6R, IL-α, sIL-1R antagonist (sIL-1RA), tumor necrosis factor receptor 60kDa/80kDa (sTNFR60/R80) in 114 MDD and 133 BD patients, and 50 healthy controls.
|
28867391 |
2018 |
|
Major Depressive Disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Increased TNF-α R1 was associated with impaired glutamatergic neurotransmission of caudate nucleus and ACC in MDD patients, particularly in the TRD.
|
29660639 |
2018 |
|
Major Depressive Disorder
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The aim was to examine the immediate and long-term changes in the TNFα level and their associations with symptom reduction in patients with MDD during ECT.
|
29670819 |
2018 |
|
Major Depressive Disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
We measured the serum cytokine levels (IL-1β, IL-6, IFN-γ, and TNFα), and whole-brain cortical thickness and hippocampal subfield volumes on brain magnetic resonance imaging (MRI) using surface-based morphometry in 40 patients with MDD and 47 healthy volunteers (controls).
|
29968776 |
2018 |
|
Major Depressive Disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Participants with low levels of TNF-α were at reduced risk of MDD compared to participants with no TNF-α [those with a TNF-α of 1- <50 pg/ml titres had an aOR = 0.35(95% CI,0.10-1.16)], but as the level of TNF-α increased, the risk of MDD increased, and in particular participants with high levels of TNF-α (of 500 or above) were at a significantly increased risk of MDD [e.g. those with a TNF-α of 500- < 1000 pg/ml titres had an aOR = 3.98 (95% CI,1.29-12.33)] compared to participants with no TNF-α.
|
29298663 |
2018 |
|
Major Depressive Disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
To investigate cytokine profiles in patients with MDD, we examined the levels of the pro-inflammatory cytokines interleukin (IL)-1β, IL-6, IL-8, and tumor necrosis factor (TNF)-α, and those of the anti-inflammatory cytokines IL-10 and transforming growth factor (TGF)-β1 in antidepressant drug-naïve patients with MDD.
|
29856741 |
2018 |
|
Major Depressive Disorder
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A consistent body of research has confirmed that patients with major depressive disorder (MDD) have increased concentrations of pro-inflammatory cytokines, including IL-6, TNF-α, IL-1β, the soluble IL-2 receptor, and C-reactive protein, compared to controls; however, there is limited information on IL-17A in MDD.
|
29069253 |
2018 |